Navigation Links
Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2011 Results
Date:9/22/2011

m its historical results or from any results expressed or implied by such forward-looking statements. Palatin's actual results may differ materially from those discussed in the forward-looking statements for reasons including, but not limited to, results of clinical trials, regulatory actions by the Food and Drug Administration and the need for regulatory approvals, Palatin's ability to fund development of its technology and establish and successfully complete clinical trials, the length of time and cost required to complete clinical trials and submit applications for regulatory approvals, products developed by competing pharmaceutical, biopharmaceutical and biotechnology companies, commercial acceptance of Palatin's products, and other factors discussed in Palatin's periodic filings with the Securities and Exchange Commission. Palatin is not responsible for updating for events that occur after the date of this press release. PALATIN TECHNOLOGIES, INC.and SubsidiaryConsolidated Statement of Operations(unaudited)Quarter Ended June 30, Year Ended June 30,2011201020112010REVENUESLicense and contract

$
24,691$
74,957$
497,540$ 14,180,727Grants

131,149-977,917-Total revenues

155,840674,9571,475,45714,180,727OPERATING EXPENSES:Research and development

3,217,3853,554,52110,377,01912,293,910General and administrative

1,525,0261,374,3204,751,8244,901,203Total operating expenses

4,742,4114,928,84115,128,84317,195,113Loss from operations

(4,586,571)(4,253,884)(13,653,386)(3,014,386)OTHER INCOME (EXPENSE):Investment income

26,91621,36599,258141,635Interest expense

(4,999)(3,862)(10,606)(13,165)Decrease/(increase) in fair value of warrants

1,255,425-(2,266)-Gain on sale of securities

--119,346-Gain/(loss) on disposition of supplies and equipment

--(5,666)95,000Total other income, net

1,277,34217,503200,066223,470Loss before income taxes

(3,309,229)(4,236,381)(13,453,320)(2,
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Palatin Technologies, Inc. Reports Positive Results of Phase 2a Clinical Study with PL-3994 for the Treatment of Heart Failure
2. Palatin Technologies, Inc. Revised Call-In Number for Teleconference and Webcast to be held on September 30, 2008
3. Palatin Technologies to Report Fiscal Year 2009 First Quarter Results; Conference Call and Webcast on November 17, 2008
4. Palatin Technologies Receives Notification Letter from NYSE Alternext US
5. Palatin Technologies to Report Fiscal Year 2009 Second Quarter Results; Conference Call and Webcast on February 17, 2009
6. Palatin Technologies Listing Compliance Plan Accepted by NYSE Alternext US
7. Palatin Technologies, Inc. Receives U.S. Patent Allowance for Heart Failure Drug Candidate
8. Palatin Technologies, Inc. Reports Positive Bremelanotide Study; Improved Safety Profile with Subcutaneous Administration
9. Palatin Technologies, Inc. to Raise $3.1 Million in Registered Direct Offering
10. Palatin Technologies to Present at the Rodman & Renshaw 11th Annual Global Investment Conference
11. Palatin Technologies, Inc. to Report Fourth Quarter and Fiscal Year 2009 Results; Teleconference and Webcast to be held on September 8, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... 2014 Research and Markets ... "Spectroscopy Equipment and Accessories - Global ... offering. This report analyzes ... Accessories in US$ Thousands by the following ... Spectrometers, NMR-EPR Spectrometers, Near Infrared (NIR) Spectrometers, ...
(Date:8/19/2014)... , Aug. 19, 2014 /PRNewswire/ - iCo Therapeutics Inc. ... today reported results of its Oral Amphotericin B ... reservoirs.  The study, conducted by ImmuneCarta®, the immune ... vitro effectiveness of Oral Amp B in ... in individuals despite intensive treatment with antiretroviral therapy. ...
(Date:8/18/2014)... 18, 2014 /PRNewswire/ - SQI Diagnostics Inc. (TSX-V: SQD), a ... and products for advanced microarray diagnostics, today announced it ... 22 at 2:00 pm ET.  During ... a brief review of SQI,s recent commercialization progress and ... industry veteran recently appointed to the Board of Directors ...
(Date:8/18/2014)... Global HIV Infection Drug Market and Pipeline Insight is ... HIV infection and the number of deaths due to AIDS ... across the globe. It has been estimated that the death ... 2013, with the rates for children being even much lower. ... rates has been the improved access to antiretroviral drugs and ...
Breaking Biology Technology:Global Spectroscopy Equipment and Accessories - Strategic Business Report 2014 2iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 2iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 3SQI Diagnostics Announces Investor Conference Call with Dr. Allan Pronovost 2SQI Diagnostics Announces Investor Conference Call with Dr. Allan Pronovost 3Global HIV Infection Drug Market Overview 2Global HIV Infection Drug Market Overview 3Global HIV Infection Drug Market Overview 4
... Inc. (Amex:,SGN) has received its second Frost & Sullivan ... 2008, at the Frost & Sullivan Awards Banquet,Signalife was ... American Patient Monitoring. Signalife,s Chief Executive Officer, Dr.,Lowell Harmison, ... present to accept the award., Signalife, Inc. is ...
... result in longer-lasting, safer batteries for ... cars, ... Department of Energy,s,(DOE) Argonne National Laboratory and Toda Kogyo Corp. ... commercial production and,sales of Argonne,s patented composite cathode materials for ...
... March 13 Arpida Ltd,(SWX: ARPN) announced today its ... 2007 highlights, Major pipeline progress:, - Second ... its pre-specified primary endpoint, as did the first, ... iclaprim in,cSSSI initiated, - First patients enrolled in ...
Cached Biology Technology:Signalife Wins Second Frost & Sullivan Technology Award 2Signalife Wins Second Frost & Sullivan Technology Award 3Argonne's Lithium-Ion Battery Technology to be Commercialized by Japan's Toda Kogyo 2Argonne's Lithium-Ion Battery Technology to be Commercialized by Japan's Toda Kogyo 3Arpida Announces Full Year 2007 Financial Results 2Arpida Announces Full Year 2007 Financial Results 3Arpida Announces Full Year 2007 Financial Results 4Arpida Announces Full Year 2007 Financial Results 5Arpida Announces Full Year 2007 Financial Results 6Arpida Announces Full Year 2007 Financial Results 7Arpida Announces Full Year 2007 Financial Results 8Arpida Announces Full Year 2007 Financial Results 9
(Date:8/19/2014)... A team of UTSA researchers has been awarded a ... Technology and Training (NCPTT), an office of the National ... The grant will fund a one-year study of the ... of historic homes in hot, humid climates. , Radiant ... or attics that reflect heat back, thereby reducing the ...
(Date:8/19/2014)... 19, 2014A new ovoid structure discovered in the Nakhla ... a variety of minerals, and shows evidence of undergoing ... of the permafrost and mixing of surface and subsurface ... of analytical studies to determine the origin of this ... this ovoid formed, point to the most likely conclusion, ...
(Date:8/19/2014)... concentrations of African dust transported to South America ... These research findings offer new insight on the ... African dust, including the climate change-induced human health ... African dust emissions in the coming decades., Researchers ... of Marine and Atmospheric Science and colleagues analyzed ...
Breaking Biology News(10 mins):UTSA researcher awarded $38K+ to evaluate energy efficiency options for historic homes 2UTSA researcher awarded $38K+ to evaluate energy efficiency options for historic homes 3Life on Mars? Implications of a newly discovered mineral-rich structure 2Study of African dust transport to South America reveals air quality impacts 2
... historical water conditions. By synthesizing present-day data with ... trends on a regional basis for periods from which scant ... impede hydrologists, understanding of the current state of waterways and ... was the case for the rivers of the northeastern United ...
... to measure the structure of membrane proteins despite being damaged ... help fast track the development of targeted drugs using emerging ... today depend on the activity of membrane proteins, which are ... our body. A major problem for the design of ...
... crow, a forest crow living on Rota Island in the ... The extinction could happen almost twice as soon as previously ... bird management program that focuses on helping fledgling birds reach ... in psychology. Ha examined survival rates in 97 Mariana ...
Cached Biology News:CCNY-led interdisciplinary team recreates colonial hydrology 2CCNY-led interdisciplinary team recreates colonial hydrology 3Despite damage, membrane protein structure can be seen using new X-ray technology, study reveals 2Without intervention, Mariana crow to become extinct in 75 years 2